Skip to main
KMDA
KMDA logo

Kamada (KMDA) Stock Forecast & Price Target

Kamada (KMDA) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Kamada Ltd is projected to achieve a year-over-year revenue increase of 13% and a 19% rise in adjusted EBITDA for fiscal year 2024, indicating robust financial growth. For 2025, the company anticipates total revenues between $178 million to $182 million and adjusted EBITDA between $38 million to $42 million, reflecting approximately 12% and 17% increases respectively, underscoring Kamada's commitment to driving growth through its proprietary and distribution segments. With a strong financial position, including an expected cash balance of $78 million, Kamada is strategically poised to attract Growth at a Reasonable Price (GARP) investors, particularly those interested in niche therapeutic opportunities.

Bears say

Kamada Ltd faces significant risks that could adversely impact its revenue and growth potential, primarily centered around the performance and regulatory approval of its core product, IH-AAT. The expected challenges in achieving peak commercial revenue estimates for AAT (IV and IH) products may stem from limited market size, penetration rates, and pricing strategies. Moreover, the enrollment difficulties in clinical studies due to the rarity of the disease heighten uncertainties regarding the success of its pipeline and overall business outlook.

Kamada (KMDA) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kamada and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kamada (KMDA) Forecast

Analysts have given Kamada (KMDA) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Kamada (KMDA) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kamada (KMDA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.